Format

Send to

Choose Destination
Oncotarget. 2015;6(12):9718-27.

Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.

Author information

1
Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia.
2
Tartis-Aging LLC, Moscow, Russia.
3
Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA.
4
Everon Biosciences, Inc., Buffalo, NY, USA.

Abstract

Benign prostatic hyperplasia (BPH) is the most common age-related disease in men. Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively. We found that Rapatar prevented hypertrophic and hyperplastic abnormalities and degenerative alterations in both BPH models. Rapatar normalized weight of the lateral lobes in sulpiride-induced BPH, the most relevant animal model of human BPH. Unlike Finasteride, a standard therapy of BPH, Rapatar reduced inflammation caused by sulpiride. No obvious side effects of Rapatar were detected. Our data provide a rationale for clinical trials of Rapatar in patients suffering from BPH.

KEYWORDS:

aging; benign prostatic hyperplasia; gerotarget; mTOR; rapamycin

PMID:
25991667
PMCID:
PMC4496392
DOI:
10.18632/oncotarget.3929
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center